SGLT2 inhibitors, cardiovascular outcomes, and mortality across the spectrum of kidney disease: A systematic review and meta-analysis
Authors' conclusion
SGLT2 inhibitors are associated with reductions in cardiovascular outcomes and mortality. Greater reductions in MACE are expected in subjects in high-risk groups for kidney disease.
Study context
- Population
- Participants of large randomized placebo-controlled SGLT2i trials, across KDIGO and UACR groups; median follow-up 2.5 years
- Participants
- 97,412 participants14 trials
- Comparison
- SGLT2i vs placebo
- Outcome
- Effect on MACE across KDIGO and UACR groups
Methodological detailsplacebo-controlled trials, minimum duration one year, random-effects model, RoB 2.0, GRADE, Risk of bias was overall low
- Placebo-controlled trials
- Minimum duration one year
- Random-effects model
- RoB 2.0
- GRADE
- Risk of bias was overall low
Pooled result
As reported in the abstract
SGLT2 inhibitors vs PlaceboHazard ratio (95 % CI)P value
KDIGO Very High; P for interaction across KDIGO groups
0.72(0.61–0.86)
P = 0.038for interactionUACR > 300 mg/g; P for interaction across UACR groups
0.76(0.68–0.86)
P = 0.008for interactionFurther pooled results
| Outcome | HR (95 % CI) | |
|---|---|---|
| Overall MACE | 0.89 (0.85–0.93) | |
| Overall CV death or HHF | 0.78 (0.75–0.82) | |
| Overall all-cause death | 0.89 (0.83–0.94) | |
| Overall HHF | 0.71 (0.67–0.75) | |
| 0.512Hazard ratio (log scale) |
Original publication
SGLT2 inhibitors, cardiovascular outcomes, and mortality across the spectrum of kidney disease: A systematic review and meta-analysis. Diabetes Res Clin Pract. Published 18 November 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →